Literature DB >> 30256751

Perioperative Nutritional Support With Beta-hydroxy-beta-methylbutyrate, Arginine, and Glutamine in Surgery for Abdominal Malignancies.

Noriko Wada1, Yukinori Kurokawa1, Koji Tanaka1, Yasuhiro Miyazaki1, Tomoki Makino1, Tsuyoshi Takahashi1, Hiroshi Wada1, Makoto Yamasaki1, Makoto Yamasaki1, Kiyokazu Nakajima1, Hidetoshi Eguchi1, Shuji Takiguchi1, Masaki Mori1, Yuichiro Doki1.   

Abstract

Although beta-hydroxy-beta-methylbutyrate (HMB), arginine (Arg), and glutamine (Gln) may contribute to wound healing, no prospective studies have investigated the efficacy of a compound consisting of HMB, Arg, and Gln (HMB/Arg/Gln) for reducing wound complications following open abdominal surgery.
OBJECTIVE: This study evaluates the usefulness of perioperative nutrition using HMB/Arg/Gln in patients who were scheduled to undergo open surgery for abdominal malignancies in a randomized controlled trial.
MATERIALS AND METHODS: Patients scheduled for open surgery for abdominal malignancies were randomized to receive HMB/Arg/Gln (1.2 g HMB, 7 g L-Arg, and 7 g L-Gln) or placebo (isocaloric juice). The supplements were provided once daily for 3 days preoperatively and once daily for 7 days postoperatively. The primary endpoint was the incidence of wound complications. Secondary endpoints included the incidence of other complications, postoperative duration of hospital stay, total-body skeletal muscle mass, handgrip strength, and skin water content.
RESULTS: Sixty-one patients were randomly assigned to either the HMB/Arg/Gln (n = 31) or the placebo (n = 30) group. One patient in the HMB/Arg/Gln group was ineligible because laparoscopic surgery was performed; thus, 60 patients were analyzed. The incidence of wound complications (20%) was the same in both groups (P = 1.000). There were no significant differences in the incidence of other complications, body composition, handgrip strength, or skin water content between the 2 groups. Serum growth hormone (GH) levels were significantly higher for patients whose total intake was > 80% of planned volume in the HMB/Arg/Gln group.
CONCLUSIONS: The incidence of wound complications would not be reduced by perioperative HMB/Arg/Gln administration in patients who underwent open surgery. The efficacy of HMB/Arg/Gln for increasing serum GH levels needs to be validated in another large-scale randomized controlled trial.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30256751

Source DB:  PubMed          Journal:  Wounds        ISSN: 1044-7946            Impact factor:   1.546


  5 in total

Review 1.  Effects of β-hydroxy β-methylbutyrate (HMB) supplementation on muscle mass, function, and other outcomes in patients with cancer: a systematic review.

Authors:  Carla M Prado; Camila E Orsso; Suzette L Pereira; Philip J Atherton; Nicolaas E P Deutz
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-03-17       Impact factor: 12.063

Review 2.  Nutrition interventions to treat low muscle mass in cancer.

Authors:  Carla M Prado; Sarah A Purcell; Alessandro Laviano
Journal:  J Cachexia Sarcopenia Muscle       Date:  2020-01-08       Impact factor: 12.910

3.  The Impact of Protein Supplementation Targeted at Improving Muscle Mass on Strength in Cancer Patients: A Scoping Review.

Authors:  Michela Zanetti; Gianluca Gortan Cappellari; Rocco Barazzoni; Gianfranco Sanson
Journal:  Nutrients       Date:  2020-07-16       Impact factor: 5.717

4.  Evaluation of the recovery after heart surgery following preoperative supplementation with a combination of beta-hydroxy-beta-methylbutyrate, L-arginine, and L-glutamine: a double-blind randomized placebo-controlled clinical trial.

Authors:  Mona Norouzi; Azadeh Nadjarzadeh; Majid Maleki; Sayyed Saeid Khayyatzadeh; Saeid Hosseini; Mehdi Yaseri; Hamed Fattahi
Journal:  Trials       Date:  2022-08-13       Impact factor: 2.728

5.  Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH).

Authors:  Lucinda Billingham; Neil Steven; Jennifer Pascoe; Aimee Jackson; Charlotte Gaskell; Claire Gaunt; Joyce Thompson
Journal:  BMC Cancer       Date:  2021-07-12       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.